TBPH Theravance Biopharma Inc.

26.96
-0.6  -2%
Previous Close 27.56
Open 27.45
Price To Book -112.33
Market Cap 1493887677
Shares 55,411,264
Volume 40,776
Short Ratio
Av. Daily Volume 185,008

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 3 dosing to commence early 2019.
TD-9855
nOH
Phase 3 data due 1H 2019.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
FDA Approval announced November 9, 2018.
Revefenacin
COPD
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD
Phase 2 commencement of dosing announced November 21, 2018.
TD-1473
Crohn's Disease
Phase 2b/3 dosing to commence late-2018 or early-2019.
TD-1473
Ulcerative Colitis
Phase 1 dosing announced November 27, 2018.
TD-8236
Asthma